Cargando…

Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report

There is a frequently encountered subset of hypothyroid patients who are refractory to standard thyroid hormone replacement treatment and require unexpectedly high doses of levothyroxine. In addition to clinical situations where hypothyroid patients are non-compliant, or where there is the possibili...

Descripción completa

Detalles Bibliográficos
Autores principales: Centanni, M., Benvenga, S., Sachmechi, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680379/
https://www.ncbi.nlm.nih.gov/pubmed/28695483
http://dx.doi.org/10.1007/s40618-017-0706-y
_version_ 1783277746786402304
author Centanni, M.
Benvenga, S.
Sachmechi, I.
author_facet Centanni, M.
Benvenga, S.
Sachmechi, I.
author_sort Centanni, M.
collection PubMed
description There is a frequently encountered subset of hypothyroid patients who are refractory to standard thyroid hormone replacement treatment and require unexpectedly high doses of levothyroxine. In addition to clinical situations where hypothyroid patients are non-compliant, or where there is the possibility of excipient-induced disease exacerbation (gluten/celiac disease), therapeutic failure may be due to impaired absorption of the administered drug. The common approach to managing patients with unusual thyroxine needs is to escalate the dose of levothyroxine until targeted TSH levels are achieved. This approach can increase the risk for prolonged exposure to supratherapeutic doses of levothyroxine, which increase the chances of adverse outcomes. Repeated adjustments of levothyroxine can also escalate the costs of treatment, as frequent office visits and laboratory tests are required to determine and maintain the desired dose. Clinicians should take a systematic approach to managing patients whom they suspect of having treatment-refractory hypothyroidism. This may include searching for, and adjusting, occult medical conditions and/or other factors that may affect the absorption of levothyroxine, before up-titrating the dose of traditional levothyroxine therapy. Depending on the underlying pathology, another approach that may be considered is to try alternative formulations of levothyroxine that are less susceptible to intolerance issues related to excipients, or, in some cases, to malabsorption. The early discovery of these factors via a thoughtful patient work-up may avoid unnecessary thyroid medication adjustments and their consequences for both patients and clinicians.
format Online
Article
Text
id pubmed-5680379
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-56803792017-11-21 Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report Centanni, M. Benvenga, S. Sachmechi, I. J Endocrinol Invest Review There is a frequently encountered subset of hypothyroid patients who are refractory to standard thyroid hormone replacement treatment and require unexpectedly high doses of levothyroxine. In addition to clinical situations where hypothyroid patients are non-compliant, or where there is the possibility of excipient-induced disease exacerbation (gluten/celiac disease), therapeutic failure may be due to impaired absorption of the administered drug. The common approach to managing patients with unusual thyroxine needs is to escalate the dose of levothyroxine until targeted TSH levels are achieved. This approach can increase the risk for prolonged exposure to supratherapeutic doses of levothyroxine, which increase the chances of adverse outcomes. Repeated adjustments of levothyroxine can also escalate the costs of treatment, as frequent office visits and laboratory tests are required to determine and maintain the desired dose. Clinicians should take a systematic approach to managing patients whom they suspect of having treatment-refractory hypothyroidism. This may include searching for, and adjusting, occult medical conditions and/or other factors that may affect the absorption of levothyroxine, before up-titrating the dose of traditional levothyroxine therapy. Depending on the underlying pathology, another approach that may be considered is to try alternative formulations of levothyroxine that are less susceptible to intolerance issues related to excipients, or, in some cases, to malabsorption. The early discovery of these factors via a thoughtful patient work-up may avoid unnecessary thyroid medication adjustments and their consequences for both patients and clinicians. Springer International Publishing 2017-07-10 2017 /pmc/articles/PMC5680379/ /pubmed/28695483 http://dx.doi.org/10.1007/s40618-017-0706-y Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Centanni, M.
Benvenga, S.
Sachmechi, I.
Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report
title Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report
title_full Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report
title_fullStr Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report
title_full_unstemmed Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report
title_short Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report
title_sort diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680379/
https://www.ncbi.nlm.nih.gov/pubmed/28695483
http://dx.doi.org/10.1007/s40618-017-0706-y
work_keys_str_mv AT centannim diagnosisandmanagementoftreatmentrefractoryhypothyroidismanexpertconsensusreport
AT benvengas diagnosisandmanagementoftreatmentrefractoryhypothyroidismanexpertconsensusreport
AT sachmechii diagnosisandmanagementoftreatmentrefractoryhypothyroidismanexpertconsensusreport